Table 2.
Relative expression of the examined genes.
| Gene | Normals | Chronic HBV hepatitis | Chronic HCV hepatitis | NAFLDb | Autoimmune diseasesc | MTX-related toxicityd | |
|---|---|---|---|---|---|---|---|
| (no. 8) | Diagnosis (no. 19) |
Relapse (no. 7) |
(no. 14) | (no. 11) | (no. 8) | (no. 2) | |
| Mean ± S.D. | Mean ± S.D. (P valuea) |
Mean ± S.D. (P valuea) |
Mean ± S.D. (P valuea) |
Mean ± S.D. (P valuea) |
Mean ± S.D. (P valuea) |
Mean ± S.D. | |
|
| |||||||
| Foxp3 | 1.11 ± 0.71 | 20.3 ± 16.0 (<.001) | 10.4 ± 5.47 (.001) | 12.7 ± 12.3 (.001) | 18.4 ± 11.9 <.001 | 16.0 ± 15.2 (.001) | 28.4 ± 27.8 |
| TGF-β 1 | 1.56 ± 1.49 | 1.10 ± 0.84 (.710) | 0.53 ± 0.31 (.053) | 0.73 ± 0.58 (.065) | 1.60 ± 1.01 (.620) | 1.43 ± 1.04 (.834) | 0.72 ± 0.17 |
| IL-10 | 1.50 ± 1.02 | 0.66 ± 1.33 (.011) | 0.20 ± 0.24 (.016) | 0.48 ± 0.77 (.017) | 0.79 ± 0.77 (.131) | 0.64 ± 0.94 (.093) | 0.59 ± 0.62 |
| Fas | 0.82 ± 0.24 | 2.25 ± 0.70 (<.001) | 2.12 ± 0.78 (.003) | 1.55 ± 1.07 (.179) | 3.51 ± 1.17 (<.001) | 1.56 ± 0.94 (.132) | 4.14 ± 0.41 |
| FasL | 1.05 ± 1.47 | 4.20 ± 2.05 (.001) | 3.05 ± 1.98 (.028) | 4.20 ± 4.09 (.004) | 3.94 ± 4.42 (.004) | 4.33 ± 3.69 (.008) | 0.49 ± 0.39 |
| TRAIL | 2.89 ± 2.04 | 7.28 ± 4.34 (.007) | 11.3 ± 6.29 (.015) | 8.86 ± 4.56 (.001) | 15.3 ± 6.64 (<.001) | 3.52 ± 2.11 (.355) | 15.3 ± 12.7 |
| Caspase-3 | 1.87 ± 1.85 | 1.13 ± 0.74 (.915) | 0.76 ± 0.43 (.366) | 1.66 ± 1.34 (.700) | 1.97 ± 1.05 (.283) | 3.19 ± 2.23 (.093) | 2.28 ± 0.66 |
| TNF-α | 3.43 ± 4.70 | 1.77 ± 3.12 (.307) | 1.54 ± 1.93 (.201) | 2.73 ± 3.58 (.544) | 8.17 ± 11.0 (.480) | 6.63 ± 9.11 (.186) | 1.21 ± 0.93 |
| IFN-γ | 1.92 ± 1.77 | 5.47 ± 5.99 (.202) | 4.17 ± 2.46 (.186) | 2.19 ± 1.77 (.628) | 4.18 ± 4.93 (.572) | 8.43 ± 7.25 (.059) | 0.37 ± 0.26 |
| IL-1β | 1.37 ± 1.05 | 0.51 ± 1.39 (.022) | 0.41 ± 0.66 (.055) | 0.33 ± 0.26 (.042) | 0.99 ± 0.95 (.322) | 1.15 ± 1.12 (.571) | 0.30 ± 0.23 |
aStatistical significance refers to comparison with the expression levels in the normal controls (Mann-Whitney U test); bNAFLD: nonalcoholic fatty liver disease; cautoimmune diseases group consists of 4 patients with autoimmune hepatitis and 4 with primary biliary cirrhosis; dMTX: methotrexate.